Johnson & Johnson’s multiple myeloma drug reduces risk of death in late-stage study


(Reuters) – Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed on Tuesday.

The injection when used with standard of care drugs, Celgene Corp’s Revlimid and dexamethasone, reduced the risk of the disease spreading or death by 44 percent at about 28 months in patients who are not eligible for stem cell transplant.